Sequential therapy of CD19 and CD22 chimeric antigen receptor T cells for relapsed/refractory mediastinal B lymphoblastic lymphoma: report of one case and review of literature
10.3760/cma.j.cn115356-20200519-00134
- VernacularTitle:CD19及CD22嵌合抗原受体T细胞序贯治疗复发难治纵隔B淋巴母细胞淋巴瘤一例并文献复习
- Author:
Bin XU
;
Di WANG
;
Mei HUANG
;
Yi XIAO
- From:
Journal of Leukemia & Lymphoma
2021;30(2):91-94
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of sequential therapy of CD19 and CD22 chimeric antigen receptor T cells (CAR-T) for relapsed/refractory mediastinal B lymphoblastic lymphoma (B-LBL).Methods:One patient with relapsed/refractory mediastinal B-LBL treated with sequential therapy of CD19 and CD22 CAR-T who was admitted to Tongji Hospital of Huazhong University of Science and Technology Tongji Medical College in March 2017 was reported. At 1, 3, 6, 12 and 18 months after CAR-T therapy, the indicators of primary disease remission were monitored and the relevant literature was reviewed.Results:The patient relapsed and progressed after third-line chemotherapy, and then received sequential therapy of CD19 and CD22 CAR-T. In the course of cellular immunotherapy, the patient presented grade 1 cytokine release syndrome. After active treatment, the patient got stable condition and was discharged. The patient came to the hospital for regular review, and the mediastinal mass of the patient was dynamically followed up. After CAR-T therapy, the mediastinal mass of the patient was significantly reduced, and the patient was in continuous remission for 18 months.Conclusions:Sequential therapy of CD19 and CD22 CAR-T provides a new therapeutic approach for relapsed/refractory B-LBL. For patients with poor curative effect of conventional chemotherapy, CAR-T therapy should be actively performed as soon as possible to improve the remission rate and the long-term prognosis of patients.
